|
|
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismBcl-2 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
一项在复发性/难治性T细胞淋巴瘤受试者中评价口服白细胞介素-2诱导性T细胞激酶抑制剂CPI-818的I/Ib期剂量递增试验
[Translation] A Phase I/Ib Dose-Escalation Trial Evaluating the Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor CPI-818 in Subjects with Relapsed/Refractory T-Cell Lymphoma
本研究的主要目的是确定CPI-818在递增剂量水平下的安全性和耐受性特征;确定CPI-818的最大耐受剂量(MTD)或最大给药剂量(MAD),以选择扩展队列剂量(ECD); 评估CPI-818在选定R/R T细胞淋巴瘤受试者中的安全性和耐受性。
[Translation] The primary objectives of this study are to determine the safety and tolerability profile of CPI-818 at escalating dose levels; to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of CPI-818 to select the expansion cohort dose (ECD); and to evaluate the safety and tolerability of CPI-818 in selected R/R T-cell lymphoma subjects.
ZN-d5单药用于中国非霍奇金淋巴瘤受试者的I期剂量递增研究
[Translation] A Phase I Dose-Escalation Study of ZN-d5 Monotherapy in Chinese Non-Hodgkin's Lymphoma Subjects
? 评估ZN-d5在NHL受试者中的安全性和耐受性
? 确定NHL受试者的MTD和/或RP2D
? 确定ZN-d5在NHL受试者中的PK特征
? 评估ZN-d5在HNL受试者中的临床活性
[Translation] ? Evaluate the safety and tolerability of ZN-d5 in NHL subjects
? Determine the MTD and/or RP2D in NHL subjects
? Determine the PK characteristics of ZN-d5 in NHL subjects
? Evaluate the clinical activity of ZN-d5 in HNL subjects
评价在健康受试者中伊曲康唑和利福平对ASC40药代动力学影响的I期开放、药物-药物相互作用研究
[Translation] A Phase I Open-label, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole and Rifampicin on the Pharmacokinetics of ASC40 in Healthy Subjects
评估伊曲康唑(一种细胞色素P450 3A(CYP3A)的强抑制剂)在健康志愿者中对ASC40的药代动力学的影响;评估利福平(CYP3A的强诱导剂)在健康志愿者中对ASC40的药代动力学的影响;评估在健康志愿者中使用伊曲康唑和利福平时ASC40的安全性和耐受性。
[Translation] To evaluate the effect of itraconazole, a strong inhibitor of cytochrome P450 3A (CYP3A), on the pharmacokinetics of ASC40 in healthy volunteers; to evaluate the effect of rifampicin, a strong inducer of CYP3A, on the pharmacokinetics of ASC40 in healthy volunteers; and to evaluate the safety and tolerability of ASC40 when itraconazole and rifampicin are used in healthy volunteers.
100 Clinical Results associated with Patheon Development Services, Inc.
0 Patents (Medical) associated with Patheon Development Services, Inc.
100 Deals associated with Patheon Development Services, Inc.
100 Translational Medicine associated with Patheon Development Services, Inc.